These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 21434800)

  • 1. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of MenB vaccines: prerequisites for clinical development.
    Sanders H; Kaaijk P; van den Dobbelsteen GP
    Expert Rev Vaccines; 2013 Jan; 12(1):31-42. PubMed ID: 23256737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 10. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 18. Postgenomics of Neisseria meningitidis for vaccines development.
    Bernardini G; Braconi D; Martelli P; Santucci A
    Expert Rev Proteomics; 2007 Oct; 4(5):667-77. PubMed ID: 17941821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Gorringe A; Halliwell D; Matheson M; Reddin K; Finney M; Hudson M
    Vaccine; 2005 Mar; 23(17-18):2210-3. PubMed ID: 15755597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.